Impact of CYP3A5 and MDR1 polymorphisms on tacrolimus and sirolimus kinetics of kidney transplant recipients

被引：0
|
作者：
Frisman, M
Renders, L
Haenisch, S
Mosyagin, I
Cascorbi, I
机构：
[1] Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24105 Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Dept Nephrol, D-24105 Kiel, Germany
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2005年 / 61卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：705 / 706
页数：2
相关论文
共 50 条
  • [41] Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
    Roy, Jean Nicholas
    Barama, Azemi
    Poirier, Charles
    Vinet, Bernard
    Roger, Michel
    [J]. PHARMACOGENETICS AND GENOMICS, 2006, 16 (09): : 659 - 665
  • [42] The impact of CYP3A5*3 and CYP3A4*22 polymorphisms on Tacrolimus pharmacokinetics in a caucasian kidney transplant cohort
    Abdel-Kahaar, E.
    Winter, S.
    Schaeffeler, E.
    Olbricht, C.
    Shipkova, M.
    Schwab, M.
    Wieland, E.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2018, 391 : S74 - S74
  • [43] Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5*3/*3 nonexpressors
    Wang, J
    Zeevi, A
    McCurry, K
    Schuetz, E
    Zheng, H
    Iacono, A
    McDade, K
    Zaldonis, D
    Webber, S
    Watanabe, RM
    Burckart, GJ
    [J]. TRANSPLANT IMMUNOLOGY, 2006, 15 (03) : 235 - 240
  • [44] Association CYP3A5 gene polymorphisms with tacrolimus blood concentration in heart transplant recipients
    Gichkun, Olga
    Shevchenko, Olga
    Koloskova, Nadegda
    Shmerko, Natalia
    Ilchuk, Maria
    Shevchenko, Alex
    [J]. TRANSPLANTATION, 2024, 108 (09) : 462 - 462
  • [45] Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay
    Li, Liang
    Li, Chuan-Jiang
    Zhang, Yan-Jun
    Zheng, Lei
    Jiang, Hai-Xia
    Si-Tu, Bo
    [J]. CLINICAL BIOCHEMISTRY, 2011, 44 (5-6) : 418 - 422
  • [46] Clinical impact of reassessed tacrolimus starting dose according to CYP3A5 genotype in kidney transplant recipients
    Largeau, B.
    Barin-Le Guellec, C.
    Longuet, H.
    Lesne, P.
    Bouvarel, A.
    Preteseille, L.
    Halimi, J. M.
    Buchler, M.
    Gatault, P.
    Noble, J.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 38 - 38
  • [47] Intestinal CYP3A5 genotype and MDR1 expression influence apparent clearance of tacrolimus in adult living-donor liver transplant recipients
    Fukudo, Masahide
    Yoshimura, Atsushi
    Yano, Ikuko
    Masuda, Satohiro
    Uesugi, Miwa
    Hosohata, Keiko
    Katsura, Toshiya
    Takada, Yasutsugu
    Uemoto, Shinji
    Inui, Ken-ichi
    [J]. THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 484 - 484
  • [48] Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients
    Cheung, Chi Yuen
    Chan, Koon Ming
    Wong, Yuen Ting
    Chak, Wai Leung
    Bekers, Otto
    van Hooff, Johannes P.
    [J]. TRANSPLANTATION PROCEEDINGS, 2019, 51 (06) : 1754 - 1757
  • [49] Influence of Cyp3A4, Cyp3A5 and ABCB1 Polymorphisms on Tacrolimus Concentrations and Rejection Risk in Indian Kidney Transplant Recipients
    Mukkavilli, Kamal Kiran
    Khan, Mohammed Shoeb A.
    Donakonda, Arun Kumar
    Gangisetty, Suma Rama Gopal
    Poojaveli, Dileena
    [J]. INDIAN JOURNAL OF TRANSPLANTATION, 2024, 18 (01) : 42 - 45
  • [50] Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients
    Chen, B.
    Zhang, W.
    Fang, J.
    Jin, Z.
    Li, J.
    Yu, Z.
    Cai, W.
    [J]. XENOBIOTICA, 2009, 39 (12) : 931 - 938
12345